Association between MDR1 gene polymorphisms and Parkinson's disease in Asian and Caucasian populations: a meta-analysis

Journal of the Neurological Sciences

Volumn 368, Issue , 2016, Pages 255-262

  Ahmed, Shiek S S J ^a   Husain, R S Akram ^a   Kumar, Suresh ^b   Ramakrishnan, V ^a  

^a CHETTINAD HOSPITAL AND RESEARCH INSTITUTE   (India)

^b Sree Balajee Medical College and Hospital   (India)

Author keywords

MDR1 gene; Meta analysis; Parkinson's disease; Polymorphism

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; ASIAN; CAUCASIAN; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC ASSOCIATION STUDY; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HOMOZYGOTE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; BIBLIOGRAPHIC DATABASE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; STATISTICS AND NUMERICAL DATA;

ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, BIBLIOGRAPHIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; P-GLYCOPROTEINS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84978698168     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.07.041     Document Type: Article

References (46)

1. [1] Brown, R.C., Lockwood, A.H., Sonawane, B.R., Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 113 (2005), 1250–1256.
2. [2] Goldenberg, M.M., Medical Management of Parkinson's disease. Pharm. Ther. 33 (2008), 590–606.
3. [3] Tsuboi, Y., Environmental-genetic interactions in the pathogenesis of Parkinson's disease. Exp. Neurobiol. 21 (2012), 123–128.
4. [4] Manthripragada, A.D., Costello, S., Cockburn, M.G., Bronstein, J.M., Ritz, B., Paraoxonase 1 (PON1), agricultural organophosphate exposure, and Parkinson disease. Epidemiology 21 (2010), 87–94.
5. [5] Zanger, U.M., Schwab, M., Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138 (2013), 103–141.
6. [6] Iskakova, A.N., Romanova, A.A., Aitkulova, A.M., Sikhayeva, N.S., Zholdybayeva, E.V., Ramanculov, E.M., Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan. BMC Genet. 17 (2016), 23–32.
7. [7] Umamaheswaran, G., Kumar, D.K., Adithan, C., Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J. Med. Res. 139 (2014), 27–65.
8. [8] Migliore, L., Coppedè, F., Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. Fundam. Mol. Mech. Mutagen. 667 (2009), 82–97.
9. [9] O'Brien, F.E., Dinan, T.G., Griffin, B.T., Cryan, J.F., Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 165 (2012), 289–312.
10. [10] Yasui-Furukori, N., Saito, M., Nakagami, T., Kaneda, A., Tateishi, T., Kaneko, S., Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006), 286–291.
11. [11] Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., Fenart, L., Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6 (2007), 650–661.
12. [12] Marzolini, C., Paus, E., Buclin, T., Kim, R.B., Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75 (2004), 13–33.
13. [13] Woodahl, E.L., Ho, R.J., The role of MDR1 genetic polymorphisms in inter individual variability in P-glycoprotein expression and function. Curr. Drug Metab. 5 (2004), 11–20.
14. [14] Tanabe, M., Ieiri, I., Nagata, N., Inoue, K., Ito, S., Kanamori, Y., Takahashi, M., Kurata, Y., J., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297 (2001), 1137–1143.
15. [15] Li, Y.H., Wang, Y.H., Li, Y., Yang, L., MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao, Acta Genet. Sin. 33 (2006), 93–104.
16. [16] Funke, C., Soehn, A.S., Tomiuk, J., Riess, O., Berg, D., Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J. Neural Transm. 116 (2009), 443–450.
17. [17] Tan, E.K., Chan, D.K., Ng, P.W., Woo, J., Teo, Y.Y., Tang, K., Wong, L.P., Chong, S.S., Tan, C., Shen, H., Zhao, Y., Lee, C.G., Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol. 62 (2005), 460–464.
18. [18] Kiyohara, C., Miyake, Y., Koyanagi, M., Fujimoto, T., Shirasawa, S., Tanaka, K., Fukushima, W., Sasaki, S., Tsuboi, Y., Yamada, T., Oeda, T., Shimada, H., Kawamura, N., Sakae, N., Fukuyama, H., Hirota, Y., Nagai, M., MDR1 C3435T polymorphism and interaction with environmental factors in risk of parkinson's disease: a case-control study in Japan. Drug Metabol. Pharmacokinet. 28 (2013), 138–143.
19. [19] Lee, C.G.L., MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J. Med. Genet. 41 (2004), e60–e70.
20. [20] Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
21. [21] Ziegler, A., Van Steen, K., Wellek, S., Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis. Breast Cancer Res. Treat. 128 (2011), 197–201.
22. [22] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
23. [23] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ (Clin. Res. Ed.) 327 (2003), 557–560.
24. [24] Lek, M., Karczewski, K., Minikel, E., Samocha, K., Banks, E., Fennell, T., A., et al. Analysis of protein-coding genetic variation in 60,706 humans. bioRxiv, 2015.
25. [25] Brinza, D., Zelikovsky, A., Case (control)-free multi-SNP combinations in case-control studies. Algorithmic Biol., 2006.
26. [26] Egger, M., Smith, G.D., Schneider, M., Minder, C., Bias in Meta-Analysis Detected by a Simple, Graphical Test. 1997.
27. [27] Westerlund, M., Belin, A.C., Anvret, A., Hakansson, A., Nissbrandt, H., Lind, C., Sydow, O., Olson, L., Galter, D., Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat. Disord. 15 (2009), 422–424.
28. [28] Momose, Y., Murata, M., Kobayashi, K., Tachikawa, M., Nakabayashi, Y., Kanazawa, I., Toda, T., Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 51 (2002), 133–136.
29. [29] Dutheil, F., Beaune, P., Tzourio, C., Loriot, M.A., Elbaz, A., Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch. Neurol. 67 (2010), 739–745.
30. [30] Tan, E.K., Drozdzik, M., Bialecka, M., Honczarenko, K., Klodowska-Duda, G., Teo, Y.Y., Tang, K., Wong, L.P., Chong, S.S., Tan, C., Yew, K., Zhao, Y., Lee, C.G., Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci. Lett. 372 (2004), 240–244.
31. [31] Zschiedrich, K., Konig, I.R., Bruggemann, N., Kock, N., Kasten, M., Leenders, K.L., Kostic, V., Vieregge, P., Ziegler, A., Klein, C., Lohmann, K., MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?. J. Neurol. 256 (2009), 115–120.
32. [32] Drozdzik, M., Bialecka, M., Mysliwiec, K., Honczarenko, K., Stankiewicz, J., Sych, Z., Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13 (2003), 259–263.
33. [33] Furuno, T., Landi, M.T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., Zanger, U.M., Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12 (2002), 529–534.
34. [34] Bertram, L., Tanzi, R.E., The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115 (2005), 1449–1457.
35. [35] Cannon, J.R., Greenamyre, J.T., The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 124 (2011), 225–250.
36. [36] Chin-Chan, M., Navarro-Yepes, J., Quintanilla-Vega, B., Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front. Cell. Neurosci., 9, 2015, 124.
37. [37] Fulda, S., Gorman, A.M., Hori, O., Samali, A., Cellular stress responses: cell survival and cell death. Int. J. Cell Biol. 20 (2010), 214–224.
38. [38] Modgil, S., Lahiri, D.K., Sharma, V.L., Anand, A., Role of early life exposure and environment on neuro-degeneration: implications on brain disorders. Transl. Neurodegener. 3 (2014), 9–18.
39. [39] Girardin, F., Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin. Neurosci. 8 (2006), 311–321.
40. [40] Loscher, W., Potschka, H., Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2 (2005), 86–98.
41. [41] Linardi, R.L., Natalini, C.C., Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs. Ciênc. Rural 36 (2006), 336–341.
42. [42] Gandhi, A., Moorthy, B., Ghose, R., Drug disposition in pathophysiological conditions. Curr. Drug Metab. 13 (2012), 1327–1344.
43. [43] Alavijeh, M.S., Chishty, M., Qaiser, M.Z., Palmer, A.M., Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2 (2005), 554–571.
44. [44] Klaassen, C.D., Aleksunes, L.M., Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 62:1 (2010), 1–96.
45. [45] Chen, B., Fang, J., Zhang, W., Jin, Z., Yu, Z., Cai, W., Detection of C1236T, G2677T/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR. J. Clin. Lab. Anal. 23 (2009), 110–116.
46. [46] Lill, C.M., Roehr, J.T., McQueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide, B.-M.M., et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PD Gene database. PLoS Genet., 8, 2012, e1002548.